TRT regrets, hematocrit spikes, and what the data actually shows

What's this video probably claiming?

Based on the caption and hashtags, @trtstrong is sharing a personal story about regretting testosterone replacement therapy, with specific focus on hematocrit elevation and blood pressure changes. The hashtag #hemoflow points to a supplement product marketed for managing blood viscosity on TRT. Videos in this genre typically follow a familiar arc: guy starts TRT, feels great for a few months, then discovers elevated red blood cell counts at a follow-up lab, panics, and either adjusts protocol or stops entirely. The creator is tagging Leviathan Nutrition, which sells hemoflow-type supplements, so there is a commercial angle here worth flagging upfront. Whether this is a genuine cautionary tale or a soft pitch for a blood-management supplement is a question the transcript will need to answer. Either way, the underlying medical topics, hematocrit elevation and cardiovascular risk on TRT, are real and worth examining honestly.

What does the science actually show?

Erythrocytosis (hematocrit above 52-54%) is the most common adverse effect of testosterone therapy, occurring in roughly 15-25% of men on injectable testosterone, compared to about 3-4% on topical formulations, according to Grech et al. (2014, Journal of Clinical Endocrinology and Metabolism). Injectable testosterone cypionate and enanthate drive larger peaks in serum testosterone, which stimulates erythropoiesis more aggressively than transdermal delivery. The TRAVERSE trial (Lincoff et al., 2023, NEJM), the largest randomized controlled trial on TRT cardiovascular outcomes to date, found no significant increase in major adverse cardiovascular events in men with hypogonadism, but the trial did note higher rates of pulmonary embolism and atrial fibrillation in the testosterone group. Hematocrit was monitored and managed in TRAVERSE, which matters. Unmanaged polycythemia increases whole-blood viscosity and theoretical clot risk, but the direct causal link between TRT-induced erythrocytosis and stroke or DVT in otherwise healthy men remains contested in the literature.

Where does the social media noise diverge from clinical reality?

The TRT-on-TikTok ecosystem has a consistent problem: it treats protocol changes and supplement additions as interchangeable with actual medical management. Hematocrit elevation on TRT has a well-established clinical response, which is dose reduction, switching delivery method, increasing injection frequency to flatten peaks, or therapeutic phlebotomy. What it does not have is strong evidence that any oral supplement meaningfully reduces hematocrit in a clinically significant way. Yet the #hemoflow hashtag and the Leviathan Nutrition tag suggest this video is at minimum adjacent to supplement marketing. Blood-donation-as-management has its own complications. Ferritin depletion from repeated phlebotomy is documented and can cause its own symptom burden (Zhu et al., 2020, Blood Advances). The framing of TRT as something you just add supplements on top of to handle side effects is a distortion of how responsible hormone management actually works under clinical supervision with serial labs.

What should you actually know?

If you are on TRT and your hematocrit is climbing above 52%, that is a clinical finding requiring a conversation with your prescribing provider, not a supplement purchase. The Endocrine Society's 2018 clinical practice guidelines recommend checking hematocrit at 3 and 6 months after starting TRT and annually thereafter. If hematocrit exceeds 54%, guidelines recommend holding testosterone, identifying reversible causes like sleep apnea, and considering dose adjustment. Blood pressure concerns on TRT are also real but more nuanced. Meta-analyses, including Corona et al. (2016, Journal of Sexual Medicine), show modest increases in systolic blood pressure of roughly 2-3 mmHg on average, which is unlikely to be clinically meaningful in most men but can matter in those with existing hypertension. Personal anecdotes about TRT regrets are valid human experiences. They are not, however, a substitute for individualized clinical assessment and real lab monitoring.